1235824-04-0

Basic information

• Product Name: (S)-N-((5-(4-(4-(3-fluorobenzyloxy)-3-(chlorophenyl)amino)quinazolin-6-yl)furan-2-yl)methylenyl)-2-methylpropane-2-sulfinamide
• Synonyms: (S)-N-((5-(4-(4-(3-fluorobenzyloxy)-3-(chlorophenyl)amino)quinazolin-6-yl)furan-2-yl)methylenyl)-2-methylpropane-2-sulfinamide
• CAS NO: 1235824-04-0
• Molecular Weight: 577.079
• Mol File: 1235824-04-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (S)-N-((5-(4-(4-(3-fluorobenzyloxy)-3-(chlorophenyl)amino)quinazolin-6-yl)furan-2-yl)methylenyl)-2-methylpropane-2-sulfinamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-((5-(4-(4-(3-fluorobenzyloxy)-3-(chlorophenyl)amino)quinazolin-6-yl)furan-2-yl)methylenyl)-2-methylpropane-2-sulfinamide(1235824-04-0)
• EPA Substance Registry System: (S)-N-((5-(4-(4-(3-fluorobenzyloxy)-3-(chlorophenyl)amino)quinazolin-6-yl)furan-2-yl)methylenyl)-2-methylpropane-2-sulfinamide(1235824-04-0)

Safety Data

• Hazardous Substances Data: 1235824-04-0(Hazardous Substances Data)

Upstream product

• 343338-28-3 (S)-2-methylpropane-2-sulfinamide 
• 231278-84-5 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde 
• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 16064-08-7 6-iodoquinazolin-4(3H)-one 

Downstream Products

• 1235820-61-7 (S)-N-(4-(3-fluorobenzyl-oxy)-3-chlorophenyl)-6-(5-(1-(amino)-2-(methylthio)ethyl)furan-2-yl)quinazolin-4-amine 
• 1235822-68-0 (S)-6-(5-(1-amino-2-(methylsulfonyl)ethyl)furan-2-yl)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)quinazolin-4-amine 
• 1235820-63-9 (S)-N-(4-(3-fluorobenzyl-oxy)-3-chlorophenyl)-6-(5-(1-(methylamino)-2-(methylthio)ethyl)furan-2-yl)quinazolin-4-amine 
• 1235822-94-2 (R)-6-(5-(1-amino-2-(methylsulfonyl)ethyl)furan-2-yl)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)quinazolin-4-amine 

Relevant articles and documents

Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates

A series of Lapatinib derivatives were designed and prepared by changing the straight alkyl side chain of Lapatinib into a branched one. ELISA assay and western blot analysis showed that these derivatives can significantly inhibit HER1/HER2 as well as their downstream signal transduction proteins. In vitro cytotoxicity assay revealed that these compounds had potent cytotoxic effect against the HER1/HER2-overexpressing cancer cells. A representive compound, 2i, showed potent in vivo antitumor activity comparable to Lapatinib, which was found to block the cell-cycle progression of BT474 cells in the G1 phase causing tumor cell apoptosis in the flow cytometry study. Moreover, the pharmacokinetic investigation on 2i also indicated it had a good performance on both absorption and elimination profiles.